Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
INOVIO Pharmaceuticals (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has announced a proposed public offering of common stock and warrants. The offering includes shares of common stock (or pre-funded warrants), along with accompanying Series A and Series B warrants.
The company will grant the underwriter, Piper Sandler & Co., a 30-day option to purchase up to an additional 15% of the securities. The offering will be conducted under a shelf registration statement that was declared effective on January 31, 2024. The final size and terms of the offering will depend on market conditions.
INOVIO (NASDAQ: INO) reported its Q1 2025 financial results and business updates. The company is on track to begin rolling submission of its Biologics License Application (BLA) for INO-3107, a potential treatment for recurrent respiratory papillomatosis (RRP), in mid-2025. Key financial metrics show a net loss of $19.7 million ($0.51 per share), improved from $30.5 million loss in Q1 2024. Operating expenses decreased to $25.1 million from $31.5 million year-over-year.
The company reported promising interim results from its Phase 1 trial of DNA-encoded monoclonal antibodies (DMAbs), showing long-lasting in vivo production. Cash position stands at $68.4 million as of March 31, 2025, expected to support operations into Q1 2026. INOVIO anticipates FDA file acceptance by year-end 2025, with potential approval (PDUFA date) in mid-2026 if granted priority review.
INOVIO, a biotechnology company developing DNA medicines, has announced its participation in several major scientific and investor conferences in May 2025. The company will present at the Citizens JMP Life Sciences Conference in New York through a fireside chat on May 8.
Notably, INOVIO will showcase new data about their lead candidate INO-3107 at multiple venues. Key presentations include:
- European Laryngological Society Annual Congress: Results showing 81% surgery reduction in adults with recurrent respiratory papillomatosis
- American Society of Gene and Cell Therapy: Treatment outcomes for recurrent respiratory papillomatosis
- American Broncho-Esophagological Association: Long-term clinical effects of INO-3107 in treating HPV 6 & 11-caused respiratory papillomatosis
Abstracts will be available on INOVIO's website after presentations, with the JMP conference webcast replay accessible for 90 days.
INOVIO (NASDAQ: INO), a biotechnology company specializing in DNA medicines, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close.
The company, which focuses on developing treatments for HPV-associated diseases, cancers, and infectious diseases, will host a live conference call and webcast at 4:30 p.m. ET on the same day. The event will include:
- A general business update presentation
- Live Q&A session with analysts
- Webcast access through http://ir.inovio.com/events-and-presentations/default.aspx
The webcast will be available for replay for 90 days following the event. This listen-only event provides investors and stakeholders an opportunity to stay updated on INOVIO's financial performance and business developments.
INOVIO (NASDAQ:INO) has announced its participation in several upcoming scientific conferences to present data on its lead candidate INO-3107 and DNA medicine technologies. At the National HPV Conference in Indianapolis on April 15, the company will present results showing a 72% overall response rate in Year 1 for treating Recurrent Respiratory Papillomatosis caused by HPV-6 & 11.
The company will also participate in the World Vaccine Congress in Washington, DC (April 21-23), where they will discuss their DNA-encoded monoclonal antibody (DMAb™) technology and DNA immunotherapeutics for cancer and viral diseases. Additionally, INOVIO will present at the Festival of Biologics in San Diego on April 23, focusing on INO-3107 for Recurrent Respiratory Papillomatosis. Abstracts will be available on INOVIO's website after the presentations.
INOVIO (NASDAQ: INO) reported its Q4 and full-year 2024 financial results, highlighting significant progress toward its first Biologics License Application (BLA) for INO-3107, targeting recurrent respiratory papillomatosis (RRP). The company resolved manufacturing issues and plans to begin rolling BLA submission in mid-2025.
Key financial metrics for 2024 include:
- Cash position: $94.1M (down from $145.3M in 2023)
- Annual revenue: $218,000 (decreased from $832,000 in 2023)
- Net loss: $107.3M or $3.95 per share (improved from $135.1M in 2023)
- R&D expenses: $75.6M (reduced from $86.7M in 2023)
Clinical highlights include promising durability data showing 50% of RRP patients achieved Complete Response in year 2, and positive interim results from their DNA-encoded monoclonal antibodies (DMAb) COVID-19 trial. The company projects its current cash position will support operations into Q1 2026, with an estimated Q1 2025 operational net cash burn of $27M.
INOVIO (NASDAQ: INO) has announced promising interim results from its ongoing Phase 1 proof-of-concept trial for DNA-encoded Monoclonal Antibodies (DMAbs) targeting COVID-19. The trial demonstrated significant achievements in durability and safety:
Key findings include:
- 100% of participants (24/24) maintained stable DMAb levels through week 72
- No anti-drug antibodies (ADA) detected across ~1,000 blood samples
- Well-tolerated with only mild, temporary injection site reactions
- Expressed DMAbs successfully bound to SARS-CoV-2 Spike protein RBD through week 72
The study, conducted in collaboration with The Wistar Institute, AstraZeneca, and the Perelman School of Medicine at the University of Pennsylvania, represents a potential breakthrough in overcoming traditional monoclonal antibody production challenges. The technology shows promise for treating infectious diseases, cancer, and metabolic disorders through long-term therapeutic protein expression.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines for HPV-associated diseases, cancers, and infectious diseases, has scheduled the release of its fourth quarter and year-end 2024 financial results for March 18, 2025, after market close.
The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a business update. The webcast will include a Q&A session with analysts and will be available for replay for 90 days through the investor relations section of INOVIO's website.
INOVIO (NASDAQ: INO) announced peer-reviewed data from its Phase 1/2 clinical trial of INO-3107 for treating recurrent respiratory papillomatosis (RRP) in Nature Communications. The trial demonstrated significant clinical benefits, with 81.3% (26/32) of patients requiring fewer surgeries post-treatment compared to the previous year. 28.1% (9/32) of patients achieved Complete Response, requiring no surgical intervention.
The treatment showed strong safety profile with only 41% reporting treatment-related adverse events, mostly mild injection site pain (31%) and fatigue (9%). INO-3107 induced lasting T cell responses specific to HPV-6 and HPV-11, with evidence of immune cells traveling to affected tissues.
INOVIO plans to submit its biologics license application (BLA) in mid-2025, seeking rolling submission and priority review. If approved, INO-3107 would become the first DNA medicine approved in the United States.
INOVIO (NASDAQ:INO) announced that it will present immunological activity data for INO-3107 at the American Association for Cancer Research – Immuno-Oncology Discovery and Innovation in Cancer Immunology conference, scheduled for February 23-26, 2025. The poster presentation will focus on the loss of detectable HPV-6 in Recurrent Respiratory Papillomatosis patients following INO-3107 treatment, specifically highlighting the induction of emergent T cells in patients who showed durable complete clinical response. The abstract will be made available on INOVIO's website after the conference.
FAQ
What is the current stock price of Inovio Pharmaceu (INO)?
What is the market cap of Inovio Pharmaceu (INO)?
